To include your compound in the COVID-19 Resource Center, submit it here.

Ophthotech's Fovista misses in third Phase III for AMD

Ophthotech Corp. (NASDAQ:OPHT) reported data from the double-blind, sham-controlled, international Phase III OPH1004 trial in about 640 patients with wet age-related macular degeneration (AMD) showing that intravitreal injections of

Read the full 298 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE